Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Medivir in connection with its rights issue
Mandate

Vinge is advising Medivir in connection with its rights issue

December 14, 2020 Capital Markets and Public M&A

Vinge is advising Medivir AB (publ) in connection with a rights issue which will provide Medivir with issue proceeds amounting to a maximum of SEK 170 million, as well as with an over-allotment option by way of a directed share issue of a maximum of approximately SEK 25 million.

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.

Medivir is listed on Nasdaq Stockholm, Small Cap.

Vinge’s team mainly consisted of Dain Hård Nevonen, Amanda Knutsson, Julia Hirschberg and Olof Löfvenberg.

Related

Vinge advises Symrise on its public offer for Probi

 Symrise AG has announced a public cash offer to the shareholders of Probi AB (publ) (“Probi”). The offer values Probi at approximately SEK 3,988 million. The shares in Probi are traded on Nasdaq Stockholm, Mid Cap.
November 20, 2024

Vinge advises Oxx in conjunction with an investment in Kodiak Hub

 Kodiak Hub, a Swedish software as a service (SaaS) company, which offers its customers an AI-based software platform, has performed a capital procurement of EUR 6 million. The venture capital fund Oxx, which invests in SaaS companies, is the largest investor.
November 20, 2024

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

 Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.
November 19, 2024